Inhibition of c-FLIP by RNAi enhances sensitivity of the human osteogenic sarcoma cell line U2OS to TRAIL-induced apoptosis

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 6, 2015, Pages 2251-2256

  Zhang, Ya Ping ^a   Kong, Qing Hong ^a   Huang, Ying ^a   Wang, Guan Lin ^a   Chang, Kwen Jen ^a  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

c FLIP; Osteogenic sarcoma; RNA interference TRAIL; U2OS cells

Indexed keywords

CASPASE; CFLAR PROTEIN, HUMAN; FLICE INHIBITORY PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; BONE TUMOR; CELL PROLIFERATION; DRUG POTENTIATION; FLOW CYTOMETRY; GENETICS; HUMAN; METABOLISM; OSTEOSARCOMA; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASES; CELL PROLIFERATION; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; OSTEOSARCOMA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED;

EID: 84929223645     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.6.2251     Document Type: Article

References (31)

1. Abedini MR, Qiu Q, Yan X, et al (2004). Possible role of FLICK-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene, 23, 6997-7004.
2. Brummelkamp TR, Bernards R, Agami R (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science, 296, 550-3.
3. Carlo-Stella C, Lavazza C, Locatelli A, et al (2007). Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res, 13, 2313-7.
4. Cai Q, Sun H, Peng Y, et al (2011). A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem, 54, 2714-26.
5. Djerbi M, Screpanti V, Catrina AI, et al (1999). The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med, 190, 1025-32.
6. Debatin KM, Krammer PH (2004). Death receptors in chemotherapy and cancer. Oncogene, 23, 2950-66.
7. Elnemr A, Ohta T, Yachie A, et al (2001). Human pancreatic cancer cells disable function of Fas receptors at several levels in fas signal transduction pathway. Int J Oncol, 18, 311-6.
8. Gao S, Wang H, Lee P, et al (2006). Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J Mol Endocrinol, 36, 463-83.
9. Hernandez A, Wang QD, Schwartz SA, et al (2001). Sensitization of human colon cancer cells to TRAIL-mediated apoptosis. J Gastrointest Surg, 5, 56-65.
10. Iannitti T, Morales-Medina JC, Palmieri B (2014). Phosphorothioate oligonucleotides: effectiveness and toxicity. Curr Drug Targets, 15, 663-73.
11. Li CL, Chang L, Guo L, et al (2014). β-elemene induces caspase-dependent apoptosis in human glioma cells in vitro through the upregulation of bax and fas/fasl and downregulation of bcl-2. Asian Pac J Cancer Prev, 15, 10407-12.
12. Micheau O, Thome M, Schneider P, et al (2002). The long form of FLIP is an activator of caspase-8 at the fas death-inducing signaling complex. J Biol Chem, 277, 45162-71.
13. Mezzanzanica D, Balladore E, Turatti F, et al (2004). CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin Cancer Res, 10, 5202-14.
14. Marina N, Gebhardt M, Teot L, et al (2004). Biology and therapeutic advances for pediatric osteosarcoma. Oncologist, 9, 422-4.
15. Mori T, Doi R, Toyoda E, et al (2005). Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Surgery, 138, 71-7.
16. Mirabello L, Troisi RJ, Savage SA (2009). Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveilance, epidemiology, and end results program. Cancer, 115, 1531-43.
17. Mollaie HR, Monavari SH, Arabzadeh SA, et al (2013). RNAi and miRNA in viral infections and cancers. Asian Pac J Cancer Prev, 14, 7045-56.
18. Marczak A, Denel-Bobrowska M, Rogalska A, et al (2014). Cytotoxicity and induction of apoptosis by formamidinodoxorubicins in comparison to doxorubicin in human ovarian adenocarcinoma cells. Environ Toxicol Pharmacol, 39, 369-83.
19. Nakajima A, Kojima Y, Nakayama M, et al (2008). Downregulation of c-FLIP promotes caspase-dependent JNK activation and reactive oxygen species accumulation in tumor cells. Oncogene, 27, 76-84.
20. Okano H, Shiraki K, Inoue H, et al (2003). Cellular FLICK/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest, 83, 1033-43.
21. Paddison PJ, Caudy AA, Bernstein E, et al (2002). Short hairpin RNAs (shRNAs) induce sepuence-specific silencing in mammalian cells. Genes Dev, 16, 948-58.
22. Rao DD, Wang Z, Senzer N, Nemunaitis J (2013). RNA interference and personalized cancer therapy. Discov Med, 15, 101-10.
23. Safa AR (2012). c-FLIP, a master anti-apoptotic regulator. Exp Oncol, 34, 176-84.
24. Soares PI, Dias SJ, Novo CM, et al (2012). Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment. Mini Rev Med Chem, 12, 1239-49.
25. Thorburn A (2004). Death receptor-induced cell killing. Cell Signal, 16, 139-44.
26. Ullenhag GJ, Mukherjee A, Watson NF, et al (2007). Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res, 13, 5070-5.
27. Valnet-Rabier MB, Challier B, Thiebault S, et al (2005). c-FLIP protein expression in burkitt's lymphomas is associated with a poor clinical outcome [J]. Br J Haematol, 128, 767-73.
28. Wiley SR, Schooley K, Smolak PJ, et al (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3, 673-82.
29. Woo SM, Min KJ, Kwon TK (2012). Calyculin A causes sensitization to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by ROS-mediated down-regulation of cellular FLICE-inhibiting protein (c-FLIP) and by enhancing death receptor 4 mRNA stabilization. Apoptosis, 17, 1223-34.
30. Zhang X, Jin TG, Yang H, et al (2004). Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res, 64, 7086-91.
31. Zhu JY, Giaisi M, Kohler R, et al (2009). Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression. Cell Death Differ, 16, 1289-99.